Oncorus to Present at Chardan 4th Annual Genetic Medicines Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oncorus, a clinical stage biopharmaceutical company specializing in viral immunotherapies for cancer treatment, announced that its CEO, Theodore A. Ashburn, will present at the Chardan 4th Annual Genetic Medicines Conference on October 6, 2020, at 4:15 p.m. ET. The company is advancing its lead candidate, ONCR-177, which utilizes a proprietary oncolytic HSV-1 platform designed to target and destroy tumor cells while enhancing the immune response against cancers. For more information, visit www.oncorus.com.
Details
News Market Reaction – ONCR
The recorded move for ONCR in the trading session of this news was -1.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced that its President and Chief Executive Officer, Theodore (Ted) A. Ashburn, M.D., Ph.D., will present a company overview at the Chardan 4th Annual Genetic Medicines Conference, to be held virtually on Tuesday, October 6, 2020 at 4:15 p.m. ET.
About Oncorus
Oncorus is a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients. Using its two distinct proprietary platforms, the Company is developing a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Oncorus’ lead product candidate, ONCR-177, is an intratumorally administered viral immunotherapy based on its oncolytic HSV-1 platform, referred to as the oHSV Platform, which leverages the Herpes Simplex Virus type 1, or HSV-1, a virus which has been clinically proven to effectively treat certain cancers. For more information, please visit www.oncorus.com.
Investors:
John McCabe
ir@oncorus.com
Media:
Liz Melone
media@oncorus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.